Babylon Holdings Ltd

$ Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000186639023000089 Filed on May 10, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1

Balance Sheet

Concept	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$25.28M	$275.0M
YoY Change	-90.81%	85830.63%
Cash & Equivalents	$25.58M	$275.0M
Short-Term Investments		$0.00
Other Short-Term Assets	$127.5M	$27.43M
YoY Change	364.82%	2370.72%
Inventory
Prepaid Expenses	$9.871M
Receivables	$15.40M	$27.98M
Other Receivables	$6.387M	$0.00
Total Short-Term Assets	$183.1M	$330.4M
YoY Change	-44.58%	23003.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.04M	$45.71M
YoY Change	-73.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$24.91M	$252.2M
YoY Change	-90.12%	-26.9%
TOTAL ASSETS
Total Short-Term Assets	$183.1M	$330.4M
Total Long-Term Assets	$24.91M	$252.2M
Total Assets	$208.0M	$582.6M
YoY Change	-64.3%	68.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.893M	$25.20M
YoY Change	-76.61%
Accrued Expenses	$39.30M	$37.89M
YoY Change	3.73%	10139.46%
Deferred Revenue	$19.09M
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$5.301M
YoY Change
Total Short-Term Liabilities	$171.6M	$149.8M
YoY Change	14.5%	40399.46%
LONG-TERM LIABILITIES
Long-Term Debt	$295.4M	$282.3M
YoY Change	4.66%
Other Long-Term Liabilities	$56.03M	$63.76M
YoY Change	-12.14%	103.91%
Total Long-Term Liabilities	$295.4M	$346.0M
YoY Change	-14.62%	1006.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$171.6M	$149.8M
Total Long-Term Liabilities	$295.4M	$346.0M
Total Liabilities	$523.1M	$503.0M
YoY Change	3.98%	1489.91%
SHAREHOLDERS EQUITY
Retained Earnings	-$900.0M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$315.1M	$79.53M
YoY Change
Total Liabilities & Shareholders Equity	$208.0M	$582.6M
YoY Change	-64.3%	68.16%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001866390
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	us-gaap	Discontinued Operation Gain Loss On Disposal Statement Of Income Or Comprehensive Income Extensible Enumeration DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2022#GainLossOnSaleOfBusiness
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P9M
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-40952
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	BABYLON HOLDINGS LIMITED
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	Y9
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1638964
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	2500 Bee Cave Road
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Building 1 - Suite 400
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Austin
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	78746
CY2023Q1	dei	City Area Code CityAreaCode	512
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	967-3787
CY2023Q1	dei	Security12b Title Security12bTitle	Class A ordinary shares, par value, $0.001056433113 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	BBLN
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25614074	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25582000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43475000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15404000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15524000	usd
CY2023Q1	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	14897000	usd
CY2022Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	17502000	usd
CY2023Q1	bbln	Prepayments And Contract Assets Current PrepaymentsAndContractAssetsCurrent	18404000	usd
CY2022Q4	bbln	Prepayments And Contract Assets Current PrepaymentsAndContractAssetsCurrent	18349000	usd
CY2023Q1	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	108797000	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	125275000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	183084000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	220125000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12039000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12658000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12870000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13327000	usd
CY2023Q1	us-gaap	Assets Assets	207993000	usd
CY2022Q4	us-gaap	Assets Assets	246110000	usd
CY2023Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	5893000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	9600000	usd
CY2023Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	4046000	usd
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	4839000	usd
CY2023Q1	bbln	Accruals Liabilities And Other Liabilities Current AccrualsLiabilitiesAndOtherLiabilitiesCurrent	40000000	usd
CY2022Q4	bbln	Accruals Liabilities And Other Liabilities Current AccrualsLiabilitiesAndOtherLiabilitiesCurrent	30029000	usd
CY2023Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	4791000	usd
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	4791000	usd
CY2023Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	9280000	usd
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	8475000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	19094000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	18710000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5023000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5102000	usd
CY2023Q1	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	70351000	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	74717000	usd
CY2023Q1	bbln	Premium Deficiency Reserve Current PremiumDeficiencyReserveCurrent	13103000	usd
CY2022Q4	bbln	Premium Deficiency Reserve Current PremiumDeficiencyReserveCurrent	6124000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	171581000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	162387000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	295449000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	278028000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	42790000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	46160000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12983000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14056000	usd
CY2023Q1	bbln	Derivative Liability Warrant Noncurrent DerivativeLiabilityWarrantNoncurrent	0	usd
CY2022Q4	bbln	Derivative Liability Warrant Noncurrent DerivativeLiabilityWarrantNoncurrent	711000	usd
CY2023Q1	bbln	Derivative Liability Contingent Consideration Earnout Liability DerivativeLiabilityContingentConsiderationEarnoutLiability	252000	usd
CY2022Q4	bbln	Derivative Liability Contingent Consideration Earnout Liability DerivativeLiabilityContingentConsiderationEarnoutLiability	667000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	523055000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	502009000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	581215000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	576585000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-900001000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-836772000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3707000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4272000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-315062000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-255899000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	207993000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	246110000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	311120000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	266446000	usd
CY2023Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	283906000	usd
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	247552000	usd
CY2023Q1	bbln	Clinical Care Delivery Expense ClinicalCareDeliveryExpense	16416000	usd
CY2022Q1	bbln	Clinical Care Delivery Expense ClinicalCareDeliveryExpense	23927000	usd
CY2023Q1	bbln	Platform And Application Expenses PlatformAndApplicationExpenses	8594000	usd
CY2022Q1	bbln	Platform And Application Expenses PlatformAndApplicationExpenses	13748000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4476000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17314000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	48393000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	55649000	usd
CY2023Q1	bbln	Premium Deficiency Reserve Income Expense PremiumDeficiencyReserveIncomeExpense	-2494000	usd
CY2022Q1	bbln	Premium Deficiency Reserve Income Expense PremiumDeficiencyReserveIncomeExpense	-6868000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1237000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3078000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-54396000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-101690000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	8819000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	5982000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	161000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	255000	usd
CY2023Q1	bbln	Remeasurement Gain Loss On Financial Instruments RemeasurementGainLossOnFinancialInstruments	336000	usd
CY2022Q1	bbln	Remeasurement Gain Loss On Financial Instruments RemeasurementGainLossOnFinancialInstruments	78773000	usd
CY2023Q1	bbln	Gain Loss On Settlement Of Derivative Liability GainLossOnSettlementOfDerivativeLiability	155000	usd
CY2022Q1	bbln	Gain Loss On Settlement Of Derivative Liability GainLossOnSettlementOfDerivativeLiability	0	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-27000	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-447000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-646000	usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-63236000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29091000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-63229000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-29100000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-565000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-3639000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-565000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3639000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-63794000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32739000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.53
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.53
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.71
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.71
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25025645	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25025645	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17038663	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17038663	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-161367000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-29100000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3639000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	-541000	usd
CY2022Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	345000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	9174000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-184736000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-255899000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-63229000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-565000	usd
CY2023Q1	bbln	Stock Issued During Period Value Bridge Financing StockIssuedDuringPeriodValueBridgeFinancing	1805000	usd
CY2023Q1	bbln	Adjustments To Additional Paid In Capital Shares Issued In Derivative Liability Warrants Exchanged AdjustmentsToAdditionalPaidInCapitalSharesIssuedInDerivativeLiabilityWarrantsExchanged	617000	usd
CY2023Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	-42000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2167000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-315062000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-63229000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-29100000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-8658000	usd
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-5727000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2167000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9174000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1237000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3078000	usd
CY2023Q1	bbln	Foreign Currency Transaction Gain Loss Before Tax Including Impact From Previous Basis Of Accounting ForeignCurrencyTransactionGainLossBeforeTaxIncludingImpactFromPreviousBasisOfAccounting	-27000	usd
CY2022Q1	bbln	Foreign Currency Transaction Gain Loss Before Tax Including Impact From Previous Basis Of Accounting ForeignCurrencyTransactionGainLossBeforeTaxIncludingImpactFromPreviousBasisOfAccounting	-447000	usd
CY2023Q1	bbln	Remeasurement Gain Loss On Financial Instruments RemeasurementGainLossOnFinancialInstruments	336000	usd
CY2022Q1	bbln	Remeasurement Gain Loss On Financial Instruments RemeasurementGainLossOnFinancialInstruments	78773000	usd
CY2023Q1	bbln	Premium Deficiency Reserve Income Expense PremiumDeficiencyReserveIncomeExpense	-2494000	usd
CY2022Q1	bbln	Premium Deficiency Reserve Income Expense PremiumDeficiencyReserveIncomeExpense	-6868000	usd
CY2023Q1	bbln	Gain Loss On Settlement Of Derivative Liability GainLossOnSettlementOfDerivativeLiability	155000	usd
CY2022Q1	bbln	Gain Loss On Settlement Of Derivative Liability GainLossOnSettlementOfDerivativeLiability	0	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-646000	usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2023Q1	bbln	Income Tax Expense Benefit Noncurrent IncomeTaxExpenseBenefitNoncurrent	0	usd
CY2022Q1	bbln	Income Tax Expense Benefit Noncurrent IncomeTaxExpenseBenefitNoncurrent	9000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-2886000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	3648000	usd
CY2023Q1	bbln	Increase Decrease In Prepayments And Contract Assets Current IncreaseDecreaseInPrepaymentsAndContractAssetsCurrent	55000	usd
CY2022Q1	us-gaap	Proceeds From Divestiture Of Interest In Consolidated Subsidiaries ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries	0	usd
CY2022Q1	bbln	Increase Decrease In Prepayments And Contract Assets Current IncreaseDecreaseInPrepaymentsAndContractAssetsCurrent	-4029000	usd
CY2023Q1	bbln	Increase Decrease In Accounts Payable Trade And Other And Claims Payable IncreaseDecreaseInAccountsPayableTradeAndOtherAndClaimsPayable	-3746000	usd
CY2022Q1	bbln	Increase Decrease In Accounts Payable Trade And Other And Claims Payable IncreaseDecreaseInAccountsPayableTradeAndOtherAndClaimsPayable	17640000	usd
CY2023Q1	bbln	Increase Decrease In Accrued Liabilities And Due To Related Parties Current IncreaseDecreaseInAccruedLiabilitiesAndDueToRelatedPartiesCurrent	1992000	usd
CY2022Q1	bbln	Increase Decrease In Accrued Liabilities And Due To Related Parties Current IncreaseDecreaseInAccruedLiabilitiesAndDueToRelatedPartiesCurrent	-5264000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2011000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-9941000	usd
CY2023Q1	bbln	Increase Decrease In Net Assets Liabilities Held For Sale IncreaseDecreaseInNetAssetsLiabilitiesHeldForSale	-11436000	usd
CY2022Q1	bbln	Increase Decrease In Net Assets Liabilities Held For Sale IncreaseDecreaseInNetAssetsLiabilitiesHeldForSale	0	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-417000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	1272000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38406000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-78482000	usd
CY2023Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	372000	usd
CY2022Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	2613000	usd
CY2023Q1	us-gaap	Proceeds From Divestiture Of Interest In Consolidated Subsidiaries ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries	516000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	144000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2613000	usd
CY2023Q1	bbln	Proceeds From Issuance Of Long Term Debt And Derivative Instrument ProceedsFromIssuanceOfLongTermDebtAndDerivativeInstrument	22000000	usd
CY2022Q1	bbln	Proceeds From Issuance Of Long Term Debt And Derivative Instrument ProceedsFromIssuanceOfLongTermDebtAndDerivativeInstrument	100000000	usd
CY2023Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	3153000	usd
CY2022Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	4000000	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1002000	usd
CY2023Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	42000	usd
CY2022Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-1538000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18889000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	93460000	usd
CY2023Q1	bbln	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations	-19373000	usd
CY2022Q1	bbln	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations	12365000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43475000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	262581000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1480000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25582000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	274978000	usd
CY2023Q1	us-gaap	Stock Issued1 StockIssued1	772000	usd
CY2022Q1	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2023Q1	bbln	Interest Incurred But Not Yet Paid InterestIncurredButNotYetPaid	6413000	usd
CY2022Q1	bbln	Interest Incurred But Not Yet Paid InterestIncurredButNotYetPaid	3978000	usd
CY2023Q1	bbln	Noncash Or Part Noncash Divestiture Amount Of Consideration To Be Received NoncashOrPartNoncashDivestitureAmountOfConsiderationToBeReceived	250000	usd
CY2022Q1	bbln	Noncash Or Part Noncash Divestiture Amount Of Consideration To Be Received NoncashOrPartNoncashDivestitureAmountOfConsiderationToBeReceived	0	usd
CY2023Q1	bbln	Fair Value Of Derivative Instrument Warrants FairValueOfDerivativeInstrumentWarrants	0	usd
CY2022Q1	bbln	Fair Value Of Derivative Instrument Warrants FairValueOfDerivativeInstrumentWarrants	-3418000	usd
CY2023Q1	bbln	Debt And Equity Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtAndEquityIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	1403000	usd
CY2022Q1	bbln	Debt And Equity Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtAndEquityIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	usd
CY2023Q1	bbln	Equity Value Of Consideration Given In Debt Instrument EquityValueOfConsiderationGivenInDebtInstrument	1804000	usd
CY2022Q1	bbln	Equity Value Of Consideration Given In Debt Instrument EquityValueOfConsiderationGivenInDebtInstrument	0	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify"><span style="color:#1fbfbb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business and economic factors, and various other assumptions that the Company believes are necessary to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment evolves. The Company believes that estimates used in the preparation of these Unaudited Condensed Consolidated Financial Statements are reasonable; however, actual results could differ materially from these estimates.</span></div>Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in the Consolidated Statement of Operations and Other Comprehensive Loss, and if material, are also disclosed in the Notes to Consolidated Financial Statements. Estimates that involve a significant level of estimation uncertainty and reasonably likely to have a material impact on the Consolidated Financial Statements of the Company include our impairment analyses over the carrying value of long-lived assets (including goodwill and intangible assets), certain assumptions for revenue recognition, the accounting for premium deficiency reserves, incurred but not reported (“IBNR”) amounts within claims expense, and the accounting for business combinations. Other policies that use estimates include the accounting for financial instruments and the accounting for stock-based compensation awards.
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	300000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	300000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-63200000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-29100000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-315100000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-255900000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	77700000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	104500000	usd
CY2021Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	229300000	usd
CY2022Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	80000000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	311120000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	266446000	usd
CY2023Q1	us-gaap	Contract With Customer Receivable After Allowance For Credit Loss Current ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent	15404000	usd
CY2022Q4	us-gaap	Contract With Customer Receivable After Allowance For Credit Loss Current ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent	15524000	usd
CY2023Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	8533000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	6112000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	61884000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	64870000	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	14713000	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	17731000	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	16358000	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	7207000	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	5874000	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	61884000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	64870000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	94182000	usd
CY2023Q1	bbln	Contract With Customer Liability Billed But Not Yet Recognized ContractWithCustomerLiabilityBilledButNotYetRecognized	271000	usd
CY2022	bbln	Contract With Customer Liability Billed But Not Yet Recognized ContractWithCustomerLiabilityBilledButNotYetRecognized	2696000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4674000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	21503000	usd
CY2023Q1	bbln	Contract With Customer Liability Foreign Exchange Effect ContractWithCustomerLiabilityForeignExchangeEffect	-1460000	usd
CY2022	bbln	Contract With Customer Liability Foreign Exchange Effect ContractWithCustomerLiabilityForeignExchangeEffect	9774000	usd
CY2023Q1	bbln	Contract With Customer Liability Transferred To Liability Held For Sale ContractWithCustomerLiabilityTransferredToLiabilityHeldForSale	43000	usd
CY2022	bbln	Contract With Customer Liability Transferred To Liability Held For Sale ContractWithCustomerLiabilityTransferredToLiabilityHeldForSale	731000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	61884000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	64870000	usd
CY2023Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	usd
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	311120000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	266446000	usd
CY2023Q1	us-gaap	Noncurrent Assets NoncurrentAssets	24909000	usd
CY2022Q4	us-gaap	Noncurrent Assets NoncurrentAssets	25985000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12039000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12658000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	1200000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	1700000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	400000	usd
CY2023Q1	bbln	Property Plant And Equipment Additions Foreign Currency Gain Loss PropertyPlantAndEquipmentAdditionsForeignCurrencyGainLoss	200000	usd
CY2023Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	15519000	usd
CY2022Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	17635000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	115000	usd
CY2022Q4	bbln	Prepayments And Contract Assets Current PrepaymentsAndContractAssetsCurrent	18349000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2111000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15404000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15524000	usd
CY2023Q1	bbln	Other Miscellaneous Receivables Current OtherMiscellaneousReceivablesCurrent	4523000	usd
CY2022Q4	bbln	Other Miscellaneous Receivables Current OtherMiscellaneousReceivablesCurrent	7205000	usd
CY2023Q1	us-gaap	Security Deposit SecurityDeposit	8510000	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	8481000	usd
CY2023Q1	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	1864000	usd
CY2022Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	1816000	usd
CY2023Q1	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	14897000	usd
CY2022Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	17502000	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9871000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	12237000	usd
CY2023Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	8533000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	6112000	usd
CY2023Q1	bbln	Prepayments And Contract Assets Current PrepaymentsAndContractAssetsCurrent	18404000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	6112000	usd
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	4484000	usd
CY2023Q1	bbln	Contract With Customer Asset Revenue Recognized On Contracts Not Billed ContractWithCustomerAssetRevenueRecognizedOnContractsNotBilled	7376000	usd
CY2022	bbln	Contract With Customer Asset Revenue Recognized On Contracts Not Billed ContractWithCustomerAssetRevenueRecognizedOnContractsNotBilled	4478000	usd
CY2023Q1	us-gaap	Contract With Customer Asset Reclassified To Receivable ContractWithCustomerAssetReclassifiedToReceivable	5068000	usd
CY2022	us-gaap	Contract With Customer Asset Reclassified To Receivable ContractWithCustomerAssetReclassifiedToReceivable	1914000	usd
CY2023Q1	bbln	Contract With Customer Asset Transferred To Assets Held For Sale ContractWithCustomerAssetTransferredToAssetsHeldForSale	21000	usd
CY2022	bbln	Contract With Customer Asset Transferred To Assets Held For Sale ContractWithCustomerAssetTransferredToAssetsHeldForSale	936000	usd
CY2023Q1	bbln	Contract With Customer Asset Foreign Currency Effect ContractWithCustomerAssetForeignCurrencyEffect	134000	usd
CY2022	bbln	Contract With Customer Asset Foreign Currency Effect ContractWithCustomerAssetForeignCurrencyEffect	0	usd
CY2023Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	8533000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	6112000	usd
CY2023Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	5893000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	9600000	usd
CY2023Q1	bbln	Taxation And Social Security Payable Current TaxationAndSocialSecurityPayableCurrent	2379000	usd
CY2022Q4	bbln	Taxation And Social Security Payable Current TaxationAndSocialSecurityPayableCurrent	4839000	usd
CY2023Q1	bbln	Other Miscellaneous Payables Current OtherMiscellaneousPayablesCurrent	1667000	usd
CY2022Q4	bbln	Other Miscellaneous Payables Current OtherMiscellaneousPayablesCurrent	0	usd
CY2023Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	4046000	usd
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	4839000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	39299000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28878000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	701000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1151000	usd
CY2023Q1	bbln	Accruals Liabilities And Other Liabilities Current AccrualsLiabilitiesAndOtherLiabilitiesCurrent	40000000	usd
CY2022Q4	bbln	Accruals Liabilities And Other Liabilities Current AccrualsLiabilitiesAndOtherLiabilitiesCurrent	30029000	usd
CY2023Q1	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of claims activity: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt 0 5.57pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at January 1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,475</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,628</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims incurred, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,906 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017,003 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims settled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(279,434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(991,506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims payable transferred to liabilities held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,667)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Claims payable</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,280</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,475</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	8475000	usd
CY2021Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	24628000	usd
CY2023Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	283906000	usd
CY2022	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	1017003000	usd
CY2023Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	279434000	usd
CY2022	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	991506000	usd
CY2023Q1	bbln	Liability For Unpaid Claims And Claims Adjustment Expense Transferred To Liabilities Held For Sale LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTransferredToLiabilitiesHeldForSale	3667000	usd
CY2022	bbln	Liability For Unpaid Claims And Claims Adjustment Expense Transferred To Liabilities Held For Sale LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTransferredToLiabilitiesHeldForSale	41650000	usd
CY2023Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	9280000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	-4723000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	8475000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	43201000	usd
CY2022Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	32438000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	295449000	usd
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	278028000	usd
CY2022Q1	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	0	usd
CY2023Q1	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	0	usd
CY2023Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	10200000	usd
CY2022Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	3900000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2167000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9174000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.76
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	368069	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M25D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.01
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	5792	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	40000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	21.04
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	43388	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.96
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	318889	shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y2M4D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	-4846000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	19.43
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	302031	shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y8M1D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	-4427000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1500000	usd
CY2022Q4	bbln	Derivative Instrument Liability Shares DerivativeInstrumentLiabilityShares	105000	shares
CY2023Q1	bbln	Derivative Instrument Liability Warrants Exchanged DerivativeInstrumentLiabilityWarrantsExchanged	105000	shares
CY2023Q1	bbln	Derivative Instrument Liability Shares DerivativeInstrumentLiabilityShares	0	shares
CY2023Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	252000	usd
CY2022Q4	bbln	Fair Value Measurement With Observable And Unobservable Inputs Reconciliation Recurring Basis Liability Value FairValueMeasurementWithObservableAndUnobservableInputsReconciliationRecurringBasisLiabilityValue	1378000	usd
CY2023Q1	bbln	Fair Value Measurement With Observable And Unobservable Inputs Reconciliation Recurring Basis Liability Remeasurement Prior To Settlements FairValueMeasurementWithObservableAndUnobservableInputsReconciliationRecurringBasisLiabilityRemeasurementPriorToSettlements	-60000	usd
CY2023Q1	bbln	Fair Value Measurement With Observable And Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithObservableAndUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	771000	usd
CY2023Q1	bbln	Fair Value Measurement With Observable And Unobservable Inputs Reconciliation Recurring Basis Liability Remeasurement After Settlements FairValueMeasurementWithObservableAndUnobservableInputsReconciliationRecurringBasisLiabilityRemeasurementAfterSettlements	415000	usd
CY2023Q1	bbln	Fair Value Measurement With Observable And Unobservable Inputs Reconciliation Recurring Basis Liability Value FairValueMeasurementWithObservableAndUnobservableInputsReconciliationRecurringBasisLiabilityValue	252000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-63229000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-63229000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-29100000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29100000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25025645	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25025645	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17038663	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17038663	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.53
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.53
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.71
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.71

Files In Submission

Name	View Source	Status
bbln-20230331_def.xml	Edgar Link	unprocessable
0001866390-23-000089-index-headers.html	Edgar Link	pending
0001866390-23-000089-index.html	Edgar Link	pending
0001866390-23-000089.txt	Edgar Link	pending
0001866390-23-000089-xbrl.zip	Edgar Link	pending
bbln-20230331.htm	Edgar Link	pending
bbln-20230331.xsd	Edgar Link	pending
bbln-20230331_g1.jpg	Edgar Link	pending
bbln-20230331_g2.jpg	Edgar Link	pending
exhibit103.htm	Edgar Link	pending
exhibit104.htm	Edgar Link	pending
exhibit311-ceosox302certif.htm	Edgar Link	pending
exhibit312-cfosox302certif.htm	Edgar Link	pending
exhibit321-ceosox906certif.htm	Edgar Link	pending
exhibit322-cfosox906certif.htm	Edgar Link	pending
exhibit44.htm	Edgar Link	pending
exhibit45.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
bbln-20230331_cal.xml	Edgar Link	unprocessable
bbln-20230331_lab.xml	Edgar Link	unprocessable
bbln-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bbln-20230331_htm.xml	Edgar Link	completed
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

Babylon Holdings Ltd

2023 Q2 Form 10-Q Financial Statement

#000186639023000089 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission